Are Investors ‘Skeptical’ Of Fresenius Kabi’s €495m mAbxience Acquisition?
Analyst Suggests Backers May Be Wary Until Kabi ‘Proves A Good Biosimilars Owner’
Fresenius Kabi’s proposed agreement to acquire a majority 55% stake in biosimilars firm mAbxience has been put under the microscope by one analyst, amid setbacks that have stymied the return on investment for Kabi’s nascent biosimilars unit.
